Vaccines

If authorized, this would be the first vaccine applicable to the youngest pediatric group.

A recent study examined whether immune response to the Pfizer-BioNTech COVID-19 vaccine differed by age and gender.

The filing included data from their phase 2/3 trial in this pediatric age group.

A shorter dosing period and no extra risk of suffering acute myocardial infarction means the newer 2-dose hepatitis B vaccine is an attractive option for protection.

An ECCMID study found COVID-19 primary infections were more severe than reinfections, and vaccination further reduced symptoms.

One study, presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), found waiting longer in between the first and second Pfizer-BioNTech vaccine doses boosted immune response 9-fold.

Investigators used electronic health records (EHR) to perform surveillance of the safety of 3 doses of the COVID-19 mRNA vaccines.

A group of over 60 scientists participated in a communication to the federal agency to advocate for measuring these cells in COVID-19 vaccine trials.

Investigators consider the low rate of vaccination in the rapidly increasing migrant populations in Europe, and call for improved strategies.

The investigational vaccine's findings from their phase 1/2 clinical trial were reported at the World Vaccine Congress.

With an evolving understanding of T-cells in immunity and emerging SARS-Co-V2 strains, evaluating these vital protection cells can offer researchers insights into response and how to develop future therapies and vaccines.

One study, presented this week at the Critical Care Congress, conducted a thorough analysis of all reported cases of myocarditis after mRNA COVID-19 vaccination.

The company says its first bivalent investigational vaccine, mRNA-1273.211, was efficacious against the Beta, Delta, and Omicron strains. They have identified another bivalent booster, mRNA-1273.214, which the company sees as its leading candidate for a fall 2022 scheduled dosing.

The 36-fold increase in Omicron neutralizing titers in children between 5-11 years old is providing data for the companies to be able to file for an FDA EUA in this age group.

A study presented at the SHEA 2022 conference determined how common and severe breakthrough infections were for Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccine recipients.

The investigational shots utilizing their mRNA technology platform are being studied in adults in the US.

Merck announced today that their investigational 21-valent pneumococcal conjugate vaccine, V116, was granted Breakthrough Therapy Designation by the FDA.

Adding v-safe active monitoring to VAERS passive reporting produced "most comprehensive" program, and affirmed COVID-19 vaccine safety.

Here is a rundown of the most popular stories we covered this past week.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) met today to discuss how to proceed with informing future COVID-19 vaccine strain composition and booster decisions.

After the US Food and Drug Administration (FDA) fully authorized the Pfizer-BioNTech mRNA vaccine, series-completing second doses increased substantially. However, first vaccine doses were actually administered at lower rates after the approval.

New data coming from Israel shows the Pfizer-BioNTech COVID-19 vaccine did offer some protection initially, but waning immunity occurs rapidly.

A new study found people who staunchly oppose COVID-19 vaccines were more likely to have experienced adverse childhoods, making them distrustful from a young age.

A pair of new studies in the Journal of the American Medical Association add to growing evidence that COVID-19 vaccines are safe during pregnancy, showing no increased risk for adverse outcomes among women who were vaccinated during pregnancy and their babies.

Here is a rundown of the most popular stories we covered this past week.

One day after the FDA approved second booster shots for certain vulnerable populations, the National Institute of Health (NIH) announced they have begun enrolling adult US participants in a phase 2 clinical trial to evaluate a second COVID-19 booster dose.

2 doses of the Pfizer-BioNTech vaccine reduced Omicron hospitalizations by 68% in children 5-11 and by 40% in adolescents 12-18 years old.

The Pfizer-BioNTech and Moderna mRNA vaccines were found to produce different antibody and killer T-cell responses, suggesting a “mix and match” booster approach may provide the best protection against COVID-19.

New policy appears inconsistent and, on the surface, unfair, expert says.

The new action by the federal agency now means the additional booster shot can be administered to people 50 years and older.